Document is current
Any future updates will be listed below
-
Authors
Rosenfield, Lana
Keith, Paul K.
Quirt, Jaclyn
Small, Peter
Ellis, Anne K.
- License Information
-
More Information
Article History
Received: 16 September 2024
Accepted: 13 November 2024
First Online: 27 December 2024
Declarations
:
: Ethics approval and consent to participate are not applicable to this review article.
: Not applicable.
: L. Rosenfield has received honoraria from Miravo, Regeneron and the CSACI and has been a member of an advisory board or speaker’s bureau for ALK. PK Keith has participated in advisory boards for ALK-Abello, AstraZeneca, Bausch Health, CSL Behring, GlaxoSmithKline, LEO Pharma, Miravo, Merck, Novartis, Sanofi, Takeda and Valeo. He has been a speaker for ALK-Abello, Bausch, GlaxoSmithKline, Medexus, Novartis, and Sanofi. His institution has received research grants from CSL Behring and Takeda. He has also served as a consultant to Bayer LLC, CADTH, and the Canadian Pharmacists Association. J. Quirt has participated in advisory boards for Aralez and Sanofi. A.K. Ellis has participated in advisory boards for ALK-Abello, AstraZeneca, Bausch Health, LEO Pharma, Miravo, Merck, Novartis, has been a speaker for ALK-Abello, AstraZeneca, Bausch, Miravo, Medexus, Mylan, Novartis, Pfizer, Sanofi, StallergenesGreer and Regeneron. Her institution has received research grants from ALK Abello, Aralez, AstraZeneca, Bayer LLC, Medexus, Novartis, Sanofi and Regeneron. She has also served as an independent consultant to Bayer LLC, Pharming, and Regeneron. P. Small has nothing to disclose.
